POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka Pharm.D., the companyâ€™s chairman, president and chief executive officer, will present at The Citigroup Global Healthcare Conference on Thursday, May 22, 2008 at 2:00 p.m. (ET) at the New York Hilton.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZENâ€™s efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for Treximetâ„¢, which was recently approved by the United States Food and Drug Administration for the acute treatment of migraine attacks in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The companyâ€™s common stock is traded on The Nasdaq Stock Market under the symbol â€œPOZNâ€. For detailed company information, including copies of this and other press releases, see POZENâ€™s website: www.pozen.com.
Chief Financial Officer
Director, Investor Relations